Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ulta Beauty Inc (ULTA) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

ULTA Beauty trades at $545.48, down 0.33% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings beat and raised 2026 guidance, though Q4 2025 missed expectations. Valuation metrics show a P/E of 20.55 and P/S of 1.92, with robust profitability including 46.12% ROE. Analyst consensus is strongly bullish with 59.57% buy ratings and a $624.93 price target, representing 14.6% upside potential.

ULTA presents a compelling growth story with e-commerce momentum and expansion into wellness categories, though margin compression and flat traffic pose near-term challenges. The stock offers attractive upside to analyst targets but faces execution risks amid consumer spending pressures. Institutional ownership remains strong with recent buying activity from major funds.